Key Takeaways:
Achieve Life Sciences Inc. received a Complete Response Letter from the US Food and Drug Administration for its cytisinicline New Drug Application, citing manufacturing deficiencies at a third-party facility and unresolved final product labeling. The FDA identified no issues with the drug's clinical efficacy or safety.
"The FDA's feedback provides a clear and actionable path forward," Chief Executive Officer Andrew D. Goldberg said. "Our clinical data stands on its own: two successful Phase 3 trials and a robust open-label safety study."
The CRL relates to a prior third-party manufacturing facility that received an Official Action Indicated classification from the FDA for general current Good Manufacturing Practice matters not specific to cytisinicline. Achieve had already partnered with US-based Adare Pharma Solutions as its new primary commercial manufacturer, completing analytical method technology transfer and manufacturing a first engineering batch. The company plans to resubmit the NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027.
The cytisinicline NDA is backed by a clinical program involving more than 1,500 participants. In the pivotal Phase 3 ORCA-2 and ORCA-3 trials, cytisinicline administered for six or 12 weeks alongside behavioral support demonstrated significantly greater smoking abstinence rates through week 24 compared with placebo. More than 400 participants received at least six months of cumulative cytisinicline exposure, and more than 200 received at least one year.
Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors, reducing nicotine craving symptoms and the reward associated with nicotine products. About 25 million US adults smoke combustible cigarettes, and nearly 18 million use e-cigarettes. The FDA has granted Breakthrough Therapy designation for cytisinicline as a treatment for nicotine e-cigarette cessation, a category with no currently approved therapies.
The delay pushes Achieve's potential US commercial launch into the first half of 2027, assuming the FDA accepts the resubmission and approves the NDA. Investors will watch for the Q4 2026 resubmission filing and any updates on the Adare manufacturing facility's inspection status.
This article is for informational purposes only and does not constitute investment advice.
